Enables metallodipeptidase activity and metalloendopeptidase activity. Involved in several processes, including germinal center formation; lymphocyte differentiation; and proteolysis. Acts upstream of or within negative regulation of neuron projection development; regulation of axon regeneration; and regulation of neuron migration. Located in cytoplasm and membrane. Is active in plasma membrane. Is expressed in several structures, including foregut-midgut junction; heart; immune system; lung; and nervous system. Used to study atopic dermatitis. Human ortholog(s) of this gene implicated in Alzheimer's disease; inflammatory bowel disease; and type 2 diabetes mellitus. Orthologous to human ADAM17 (ADAM metallopeptidase domain 17).
a disintegrin and metalloprotease domain 17; a disintegrin and metalloproteinase domain 17; ADAM 17; CD156b; disintegrin and metalloproteinase domain-containing protein 17; Tac; Tace; TNF-alpha convertase; TNF-alpha converting enzyme; TNF-alpha-converting enzyme
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA], IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein], 4-phenylbutyric acid inhibits the reaction [SFTPC protein mutant form results in increased expression of ADAM17 protein]
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA], IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ADAM17 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ADAM17 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA
pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of ADAM17 protein], pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of and results in increased stability of ADAM17 mRNA]
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA], IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA, [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA, [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA
polyethylene glycol-superoxide dismutase inhibits the reaction [Cyclosporine results in increased activity of ADAM17 protein], polyethylene glycol-superoxide dismutase inhibits the reaction [Cyclosporine results in increased phosphorylation of ADAM17 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 mRNA], Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA, [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [hydroquinone results in increased expression of ADAM17 protein] more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein], 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA
ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of HBEGF protein], ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein]
[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein more ...
[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein more ...
Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 mRNA], Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 protein]
Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans.